L. Agertoft (Broendby, Denmark), A. Vaessen-Verberne (Breda, The Netherlands)
Inhaled ciclesonide does not affect lower-leg growth rate or HPA-axis function in children with mild asthma
L. Agertoft, S. Pedersen (Kolding, Denmark)
|  |
Assessment of factors affecting spacer output
N. C. Schaefer, J. Owen, S. G. Devadason (Perth, Australia)
| |
Montelukast vs. fluticasone in patients aged 6 to 14 with mild persistent asthma: the MOSAIC study
P. Polos, M. L. Garcia Garcia, L. Gilles, C. A. Tozzi, B. Knorr, T. F. Reiss (Whitehouse Station, United States Of America; Madrid, Spain)
| |
Efficacy of montelukast in patients aged 2 to 5 years with mild asthma
H. Bisgaard, A. Swern, C. A. Tozzi, Q. Yu, B. Knorr, T. F. Reiss (Copenhagen, Denmark; Rahway, United States Of America)
| |
Safety of fluticasone propionate and nedocromil sodium on bone in children with asthma
V. A. Tomashevskaja, T. V. Kulichenko (Moscow, Russia)
| |
The effects of fluticasone propionate/salmeterole 50/100 μg bid in children with asthma versus beclometasone propionate 200 μg BD and fluticasone propionate 100 μg bid dry powder inhaletors
N. A. Geppe, A. V. Karpushkina, N. G. Kolossova, E. B. Yarovaya (Moscow, Russia)
| |
Rescue/acute and allergy medication use among children on asthma controller therapy
N. Travier, V. S. Kocevar, D. D. Yin, L. Laforest, E. Van Ganse (Pierre Benite, France; Whitehouse Station, United States Of America)
| |
Effects of one year of treatment with mometasone furoate metered dose inhaler (MF-MDI) on growth in children with asthma
R. F. Lemanske, R. F. Lockey, K. R. Murphy (Madison, Tampa, Omaha, United States Of America)
| |
Extrafine beclomethasone dipropionate aerosol therapy shows promising improved effect in treatment of children with stable asthma
E. Bodart, F. De Baets (Yvoir, Gent, Belgium)
| |
Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma
P. Pohunek, P. Kuna, K. De Boeck (Prague, Czech Republic; Lodz, Poland; Leuven, Belgium)
| |
Deposition of 99mTc-HFA-BDP inhaled via pMDI-spacer in asthmatic children
C. M. Roller, J. L. Owen, R. G. Troedson, P. N. Le Souef, S. G. Devadason (Perth, Australia)
| |
Montelukast x beclomethasone: a prospective randomizad multicenter trial
J. P. B. Lotufo (Sao Paulo, Brazil)
| |
Long-term efficacy of 1 year anti-inflammatory treatment in paediatric patients with mild persistent asthma
M. Henschen, E. Staikou, M. Brandis, J. Kuehr (Freiburg, Germany)
| |
Improvements in FEV1 and PEF were greater with salmeterol/fluticasone (S/F) than with beclamethasone dipropionate (BDP)
T. V. Zaharov, S. S. Kamenov, B. A. Kamenov (Dimitrovgrad, Nis, Serbia & Montenegro)
| |
Salmeterol use in day-care centres for improvement of asthma control and quality of life in children
C. Gheonea, D. A. Plesca, D. Bulucea, R. Diaconu, D. Butulescu (Craiova, Tg. Jiu, Bucharest, Romania)
| |
Salmeterol/fluticasone (seretide, S/F) used as needed improves health-related quality of life in asthmatic adolescents uncontrolled with ICS receiving inhaled short-acting β2 agonists (SAB2A)
T. V. Zaharov, S. S. Kamenov, B. A. Kamenov (Dimitrovgrad, Nis, Serbia & Montenegro)
| |
Improvements in FEV1 and PEF were greater with salmeterol/fluticasone (S/F) than with beclamethasone dipropionate (BDP)
T. V. Zaharov, S. S. Kamenov, B. A. Kamenov (Dimitrovgrad, Nis, Serbia & Montenegro)
| |
In vitro performance of a new non-electrostatic, transparent valved holding chamber (VHC) for the poorly coordinated patient
J. P. Mitchell, C. C. Doyle, V. I. Avvakoumova, M. W. Nagel (London, Canada)
| |
Audit of self-referral paediatric respiratory clinic
L. Grant, D. Cochran (Glasgow, United Kingdom)
| |